The expression of type III hyperlipoproteinemia: Involvement of lipolysis genes

European Journal of Human Genetics

Volumn 17, Issue 5, 2009, Pages 620-628

  Henneman, Peter ^a   van der Sman de Beer, Femke ^a   Moghaddam, Payman Hanifi ^b   Huijts, Petra ^a   Stalenhoef, Anton F H ^c   Kastelein, John J P ^d   van Duijn, Cornelia M ^b   Havekes, Louis M ^a,e   Frants, Rune R ^a   van Dijk, Ko Willems ^a   Smelt, Augustinus H M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; APOLIPOPROTEIN A5; APOLIPOPROTEIN C3; APOLIPOPROTEIN E2; CYTOSINE; GUANINE; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; THYMINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTRIGLYCERIDEMIA; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NETHERLANDS; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; APOLIPOPROTEIN C-III; APOLIPOPROTEINS A; BLOOD GLUCOSE; CHOLESTEROL; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; HYPERLIPOPROTEINEMIA TYPE III; HYPERTRIGLYCERIDEMIA; INSULIN; LINKAGE DISEQUILIBRIUM; LIPASE; LIPOLYSIS; LIPOPROTEIN LIPASE; MALE; MIDDLE AGED; NETHERLANDS; POLYMORPHISM, GENETIC; TRIGLYCERIDES;

EID: 67349172252     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2008.202     Document Type: Article

References (50)

1. Morganroth J, Levy RI, Fredrickson DS: The biochemical, clinical, and genetic features of type III hyperlipoproteinemia. Ann Intern Med 1975; 82: 158-174.
2. Brewer Jr HB, Zech LA, Gregg RE, Schwartz D, Schaefer EJ: NIH Conference. Type III hyperlipoproteinemia: Diagnosis, molecular defects, pathology, and treatment. Ann Intern Med 1983; 98: 623-640.
3. Smelt All, de Beer F: Apolipoprotein E and familial dysbetalipo-proteinemia: Clinical, biochemical, and genetic aspects. Semin Vasc Med 2004; 4: 249-257.
4. Mahley RW, RFll Jr SC: Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000; 1: 507-537.
5. Utermann G: Apolipoprotein E polymorphism in health and disease. Am Heart J 1987; 113: 433-440.
6. de Beer F, Stalenhoef AF, Hoogerbrugge N et al: Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158 →Cys) homozygotes is associated with hyperinsulinemia. Arterioscler Thromb Vasc Biol 2002; 22: 294-299.
7. Utermann G, Hees M, Steinmetz A: Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man. Nature 1977; 269 604-607.
8. Zhao SP, Smelt AH, Van den Maagdenberg AM et al: Plasma lipoprotein profiles of normocholesterolemic and hypercholesterolemic homozygotes for apolipoprotein E2 (Arg158→Cys) compared. Clin Chem 1994; 40: 1559-1566.
9. Mahley RW, Huang Y, Rall Jr SC: Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res 1999; 40: 1933-1949.
10. Olefsky JM, Farquhar JW, Reaven GM: Reappraisal of the role of insulin in hypertriglyceridemia. Am J Med 1974; 57: 551-560.
11. Zammit VA, Waterman IJ, Topping D, McKay G: Insulin stimulation of hepatic triacylglycerol secretion and the etiology of insulin resistance. J Nutr 2001; 131: 2074-2077.
12. Sijbrands EJ, Hoffer MJ, Meinders AE et al: Severe hyperlipidemia in apolipoprotein E2 homozygotes due to a combined effect of hyperinsulinemia and an SstI polymorphism. Arterioscler Thromb Vasc Biol 1999; 19: 2722-2729.
13. Zhang H, Reymer PW, Liu MS et al: Patients with apoE3 deficiency (E2/2, E3/2, and E4/2) who manifest with hyperlipidemia have increased frequency of an Asn 291→Ser mutation in the human LPL gene. Arterioscler Thromb Vasc Biol 1995; 15: 1695-1703.
14. Schaefer JR, Sattler AM, Hackler B et al: Hyperlipidemia in patients with apolipoprotein E2/2 phenotype: Apolipoprotein A5 S19W mutation as a cofactor. Clin Chem 2004; 50: 2214.
15. Evans D, Seedorf U, Beil FU: Polymorphisms in the apolipoprotein A5 ( APOA5) gene and type III hyperlipidemia. Clin Genet 2005; 68 369-372.
16. Evans D, Beil FU: The D9N, N291S and S447X variants in the lipoprotein lipase (LPL) gene are not associated with type III hyperlipidemia. BMC Med Genet 2007; 8: 56.
17. Talmud PJ, Humphries SE: Genetic polymorphisms, lipoproteins and coronary artery disease risk. Curr Opin Lipidol 2001; 12: 405-409.
18. Merkel M, EckeG RH, Goldberg IJ: Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res 2002; 43: 1997-2006.
19. Jansen H, Aerhoeven AJ, Sijbrands EJ: Hepatic lipase: a pro- or anti-atherogenic protein? J Lipid Res 2002; 43: 1352-1362.
20. Zambon A, Deeb SS, Pauletto P, Crepaldi G, Brunzell JD: Hepatic lipase: a marker for cardiovascular disease risk and response to therapy. Curr Opin Lipidol 2003; 14: 179-189.
21. Pennacchio LA, Olivier M, Hubacek JA et al: An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001; 294: 169-173.
22. O'Brien PJ, Alborn WE, Sloan JH et al: The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin Chem 2005; 51: 351-359.
23. Henneman P, Schaap FG, Havekes LM et al: Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism. Atherosclerosis 2007; 193: 129-134.
24. Henneman P, Schaap FG, Rensen PC, van Dijk KW, Smelt AH: Estrogen induced hypertriglyceridemia in an apolipoprotein AV deficient patient. J Intern Med 2008; 263: 107-108.
25. Assman G, Schulte H: Lipid Metabolism Disorders and Coronary Heart Disease. Results and Conclusions of the Prospective Cardiovascular Munster (PROCAM) Study. 2nd Eds. München: MMV Medizin Verlag. 1993, pp 19-67.
26. Smit M, De Knijff P, Rosseneu M et al: Apolipoprotein E polymorphism in The Netherlands and its effect on plasma lipid and apolipoprotein levels. Hum Genet 1988; 80: 287-292.
27. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA: Determinants of disease and disability in the elderly: The Rotterdam Elderly Study. Eur J Epidemiol 1991; 7: 403-422.
28. Stolk RP, Pols HA, Lamberts SW, de Jong PT, Hofman A, Grobbee DE: Diabetes mellitus, impaired glucose tolerance, and hyperinsulinemia in an elderly population. The Rotterdam Study. Am J Epidemiol 1997; 145: 24-32.
29. Havekes LM, De Knijff P, Beisiegel U, Havinga J, Smit M, Klasen E: A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res 1987; 28: 455-463.
30. Reymer PW, Groenemeyer BE, van de BR, Kastelein JJ: Apolipoprotein E genotyping on agarose gels. Clin Chem 1995; 41: 1046-1047.
31. Burstein M, Scholnick HR, Morfin R: Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res 1970; 11: 583-595.
32. Starr JI, Mako ME, Juhn D, Rubenstein AH: Measurement of serum proinsulin-like material: Cross-reactivity of porcine and human proinsulin in the insulin radioimmunoassay. J Lab Clin Med 1978; 91: 683-692.
33. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
34. Hoffer MJ, Sijbrands EJ, De Man FH, Havekes LM, Smelt AH, Frants RR: Increased risk for endogenous hypertriglyceridaemia is associated with an apolipoprotein C3 haplotype specified by the SstI polymorphism. Eur J Clin Invest 1998; 28: 807-812.
35. Hoffer MJ, Bredie SJ, Snieder H et al: Gender-related association between the -93T→G/D9N haplotype of the lipoprotein lipase gene and elevated lipid levels in familial combined hyperlipidemia. Atherosclerosis 1998; 138: 91-99.
36. Jansen H, Verhoeven AJ, Weeks L et al: Common C-to-T substitution at position -480 of the hepatic lipase promoter associated with a lowered lipase activity in coronary artery disease patients. Arterioscler Thromb Vasc Biol 1997; 17: 2837-2842.
37. Knudsen P, Antikainen M, Ehnholm S et al: A compound heterozygote for hepatic lipase gene mutations Leu334→Phe and Thr383→Met: correlation between hepatic lipase activity and phenotypic expression. J Lipid Res 1996; 37: 825-834.
38. Hegele RA, Tu L, Connelly PW: Human hepatic lipase mutations and polymorphisms. Hum Mutat 1992; 1: 320-324.
39. BarreAt JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21 263-265.
40. Miller M, Rhyne J, Chen H et al: APOC3 promoter polymorphisms C-482T and T-455C are associated with the metabolic syndrome. Arch Med Res 2007; 38: 444-451.
41. Talmud PJ, Hawe E, Martin S et al: Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet 2002; 11: 3039-3046.
42. Dammerman M, Sandkuijl LA, Halaas JL, Chung W, Breslow JL: An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci USA 1993; 90: 4562-4566.
43. Lai CQ, Parnell LD, Ordovas JM: The APOA1/C3/A4/A5 gene cluster, lipid metabolism and cardiovascular disease risk. Curr Opin Lipidol 2005; 16: 153-166.
44. Fisher RM, Benhizia F, Schreiber R et al: Enhanced bridging function and augmented monocyte adhesion by lipoprotein lipase N9: insights into increased risk of coronary artery disease in N9 carriers. Atherosclerosis 2003; 166: 243-251.
45. Talmud PJ, Stephens JW: Lipoprotein lipase gene variants and the effect of environmental factors on cardiovascular disease risk. Diabetes Obes Metab 2004; 6: 1-7.
46. Martin-Campos JM, Rico N, Bonet R, Mayoral C, Ordonez-Llanos J, Blanco-Vaca F: Apolipoprotein A5 S19W may play a role in dysbetalipoproteinemia in patients with the Apo E2/E2 genotype. Clin Chem 2006; 52: 1974-1975.
47. Olivier M, Wang X, Cole R et al: Haplotype analysis of the apolipoprotein gene cluster on human chromosome 11. Genomics 2004; 83: 912-923.
48. Chen M, Breslow JL, Li W, Leff T: Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: Correlation with changes in plasma triglyceride levels. J Lipid Res 1994; 35: 1918-1924.
49. Altomonte J, Cong L, Harbaran S et al: Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest 2004; 114: 1493-1503.
50. Julien P, Vohl MC, Gaudet D et al: Hyperinsulinemia and abdominal obesity affect the expression of hypertriglyceridemia in heterozygous familial lipoprotein lipase deficiency. Diabetes 1997; 46: 2063-2068.